19
Participants
Start Date
May 17, 2021
Primary Completion Date
November 15, 2021
Study Completion Date
December 3, 2021
Coagulation Factor VIIa variant
Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
East Carolina University, Greenville
Children's Hospital of Michigan, Detroit
Michigan State University Center for Bleeding Disorders & Clotting Disorders, East Lansing
Rush University, Chicago
University of Colorado Hemophilia and Thrombosis Center, Aurora
University of California -San Francisco, San Francisco
UC Davis Medical Center, Sacramento
Mazumdar Shaw Medical Centre, Bengaluru
St. John's Medical College Hospital, Bengaluru
Amrita Institute of Medical Sciences and Research Centre, Kochi
K. J. Somaiya Hospital and Research Centre, Mumbai
Sahyadri Super Speciality Hospital, Pune
Careggi University Hospital, Florence
Center for Thrombosis and Haemorrhagic Diseases, Milan
Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milan
Children's Hospital BambiNo Gesù, IRCCS (PEDS), Roma
City of Health and Science of Turin, Turin
Territorial Clinical Hospital, Barnaul
National Medical Hematology Research Center under the Ministry of Healthcare of the Russian Federation, Moscow
Institute of Blood Pathology and Transfusion Medicine, Department of Surgery and Clinical Transfusiology, Lviv
Lead Sponsor
Catalyst Biosciences
INDUSTRY